Research and Markets (http://www.researchandmarkets.com/research/7e1d99/pharmaceutical_pri) has announced the addition of Decision Resources, Inc.’s new report “Pharmaceutical Pricing and Reimbursement in Japan, 2008” to their offering.
Introduction
The pharmaceutical industry faces challenging times in the Japanese market. The government has expressed its desire to reward the development of innovative medicines and has promised more-generous price premiums for innovative drugs. At the same time, the government strictly controls launch prices and continues to erode prices throughout the product life cycle. There are, however, pricing changes effective in 2008 that could signal the beginning of pricing reforms that promote therapeutic innovation.
Get the Answers You Need to Shape Your Strategy
– Japan has the world’s second-largest pharmaceutical market, and the world’s largest price-controlled pharmaceutical market. How do the country’s governing agencies control the prices of newly launched prescription drugs? What types of postmarketing price cuts are in place to curb pharmaceutical expenditures?
– The reimbursement prices of new drugs in Japan are determined by confidential negotiations between the manufacturer and the Japanese Ministry of Health, Labor, and Welfare as soon as the drug wins regulatory approval. What methods are used to calculate drug reimbursement prices? What criteria are used by the governing agencies to determine the pricing method for a given drug?
– The Japanese market for generics has begun to grow steadily, albeit slowly. What factors account for the modest market share of generics in Japan? Which pharmaceutical companies are looking to capitalize on the growing demand for generics in Japan? What is the government doing to improve the generics supply and the reputation of the generics industry among patients and medical professionals?
Scope
– Overview: organization and funding of the Japanese healthcare system; soaring growth of the country’s healthcare expenditures; prescription drug prices in Japan compared with other major markets.
– Price setting: initial pricing of branded drugs; similar-efficacy pricing methods; price premiums; cost calculation method; foreign price adjustment rule.
– Postmarketing price changes: the government’s biennial National Health Insurance price revisions; price cuts for long-listed drugs; repricing in response to market expansion.
– Promoting the use of generics: evolution of the Japanese generics market; recent changes in the generics market; use of generics in hospitals; measures to improve the generics supply; increasing competition in the Japanese generics market.
Key Topics Covered:
– Executive Summary
– Strategic Considerations
– Stakeholder Implications
– Overview
– Organization and Funding of the Healthcare System
– Healthcare Expenditures
– Pharmaceutical Prices in Japan
– Price Setting
– Initial Pricing of Branded Prescription Drugs
– Similar-Effi cacy Comparison Methods
– Price Comparators
– Price Premiums
– “Me-Too” Drugs
– Cost Calculation Method
– Foreign Price Adjustment Rule
– Postmarketing Price Changes
– Biennial Price Revision
– Price Cuts for Long-Listed Drugs
– Repricing in Response to Market Expansion
– Promoting the Use of Generics
– Evolution of the Japanese Generics Market
– Recent Changes in the Generics Market
– Generics Substitution
– Use of Generics in Hospitals
– Measures to Improve the Generics Supply
– Increasing Competition in the Japanese Generics Market
– Health Technology Assessment
– Outlook for the Japanese Pricing and Reimbursement Environment
Companies Mentioned:
– Astellas
– Bayer
– Chugai Pharmaceutical
– Chuikyo (Central Social Insurance Medical Council)
– Daiichi-Sankyo
– Genzyme
– GlaxoSmithKline
– Health Policy Bureau
– Kirin
– Kissei Pharmaceutical
– Kokumin Kaihokenseido (National Health Insurance (NHI) system)
– Kyorin
– Kyowa Pharmaceutical
– Lupin
– Meiji Seika Kaisha
– Mitsubishi
– Mylan Seiyaku
– Nichi-iko
– Nidek
– Nihon Pharmaceutical Industry
– Nippon Chemiphar
– Nippon Universal Pharmaceutical
– Nippon Zenyaku Kogyo
– Novartis
– Novo Nordisk
– Pfi zer
– Ranbaxy Laboratories
– Sandoz
– Sanofi -Aventis
– Sawai
– Taiyo Yakuhin
– Takeda
– Tanabe-Mitsubishi
– Teijin
– Teva Pharmaceutical
– Towa
– Toyamakagaku
– Yakka Santei Soshiki (Drug Pricing Organization (DPO))
– Yoshitomi
– Zydus Pharma
For more information visit http://www.researchandmarkets.com/research/7e1d99/pharmaceutical_pri
Comments